- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 209/40 - Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
Patent holdings for IPC class C07D 209/40
Total number of patents in this class: 265
10-year publication summary
|
16
|
19
|
20
|
17
|
15
|
14
|
18
|
18
|
18
|
10
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Achillion Pharmaceuticals, Inc. | 164 |
23 |
| Novartis Pharma AG | 102 |
15 |
| IFM Due, Inc. | 36 |
14 |
| City of Hope | 1013 |
7 |
| Cornell University | 3361 |
7 |
| Novita Pharmaceuticals, Inc. | 23 |
7 |
| Vertex Pharmaceuticals Incorporated | 1630 |
5 |
| Purdue Research Foundation | 3732 |
5 |
| China Pharmaceutical University | 327 |
4 |
| National and Kapodistrian University of Athens | 43 |
4 |
| VALO Health, Inc. | 176 |
4 |
| BioCryst Pharmaceuticals, Inc. | 171 |
3 |
| Council of Scientific & Industrial Research | 1426 |
3 |
| Epizyme, Inc. | 375 |
3 |
| Georgetown University | 619 |
3 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 849 |
3 |
| Taipei Medical University | 208 |
3 |
| Glaxosmithkline LLC | 535 |
2 |
| F. Hoffmann-La Roche AG | 7937 |
2 |
| Boehringer Ingelheim International GmbH | 4636 |
2 |
| Other owners | 146 |